News

An active moiety of the prodrug isavuconazonium, Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal being developed to treat severe invasive and life-threatening fungal infections. The

The drug is indicated for the long-term, once-daily, add-on maintenance treatment of asthma in patients 12 years of age and older who remain symptomatic on at least inhaled

Under the new $4.8m strategic alliance, ex scientia received an upfront payment of $1m. As part of the deal, Sunovion will receive exclusive worldwide rights to the resulting

These data demonstrate that Fluzone High-Dose vaccine provided improved protection against influenza ("the flu") compared to standard-dose Fluzone vaccine (trivalent intramuscular formulation) in adults 65 years of age

The effectiveness of aripiprazole once-monthly (aripiprazole extended-release injectable suspension, for intramuscular use: Abilify Maintena) and paliperidone palmitate (paliperidone palmitate extended-release injectable suspension, for intramuscular use) in adult patients

Under the terms of the agreement, Intra-Cellular Therapies has regained all worldwide development and commercialization rights for the compounds previously licensed to Takeda. Takeda will be responsible for

The clinical-stage biotechnology company has obtained exclusive worldwide rights to use human insulin producing cells, termed "Melligen" cells, developed by University of Technology – Sydney’s (UTS) Professor Ann

Now through November 22, CVS/pharmacy customers will have the opportunity to support Stand Up To Cancer (SU2C) at the register in stores nationwide and online at www.cvs.com/SU2C. SU2C

Galecto’s TD139 is currently in Phase I development and is designed to treat idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions. TD139 is a highly potent, specific